Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.6K

Histone methyltransferases SMYD2: the potential pharmacological target on cancers and aging-related diseases

Meng Gu1, Menglin Zhu1, Jianghong Cai1

  • 1Laboratory of Drug Discovery from Natural Resources and Industrialization, Macao University of Science and Technology, Macau SAR, 999078, China.

European Journal of Medicinal Chemistry
|February 3, 2026
PubMed

Insights

Protein methylation abnormalities link to disease. This review explores SMYD2

Area of Science:

  • Epigenetics and molecular biology.
  • Cancer biology and aging research.

Background:

  • Protein methylation is crucial in disease pathogenesis.
  • SMYD2 (SET and MYND domain-containing protein 2) is implicated in cancer and aging.
  • SMYD2's precise biological roles and inhibitor development require further investigation.

Purpose of the Study:

  • To review SMYD2's mechanisms in cancer and aging.
  • To clarify the effects of SMYD2 inhibitors on various diseases.
  • To identify research gaps and propose future directions for SMYD2 inhibitor development.

Main Methods:

  • Literature review of studies on SMYD2.
  • Analysis of SMYD2's role in cancer and aging.
  • Evaluation of existing SMYD2 inhibitors and their efficacies.

Main Results:

  • SMYD2 is a key player in cancer and aging-related diseases.
  • Specific SMYD2 inhibitors show therapeutic potential.
  • Contradictory findings in current research highlight the need for further studies.

Conclusions:

  • SMYD2 is a promising therapeutic target for cancer and aging.
  • Further research on SMYD2 structure and inhibitor development is warranted.
  • This review provides insights for novel drug development strategies.
Keywords:
Aging-related diseasesCancersDrug developmentHistone methyltransferasesSMYD2

More Related Videos

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans07:04

Modeling Age-Associated Neurodegenerative Diseases in Caenorhabditis elegans

Published on: August 15, 2020

5.8K
Antibody-Free Assay for RNA Methyltransferase Activity Analysis08:31

Antibody-Free Assay for RNA Methyltransferase Activity Analysis

Published on: July 9, 2019

7.7K

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
16.2K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
956
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
617